PeterMd

About PeterMd

PeterMd has been operating since 2021, making it one of the longer-tenured providers in the compounded GLP-1 space. The platform focuses exclusively on compounded tirzepatide, with pricing between $149 and $249 per month — a competitive range for this medication class. However, the concerning signals surrounding this provider far outweigh its pricing advantage, and our editorial team has significant reservations about recommending PeterMd to readers.

The most alarming finding in our research is that PeterMd’s Trustpilot page has been removed. While there can be legitimate reasons for a Trustpilot page disappearing, in our experience reviewing dozens of telehealth providers, a removed review page is a serious red flag. It often indicates that the volume or nature of complaints triggered Trustpilot’s fraud detection systems, or that the company itself requested removal to hide negative feedback. Either scenario should give prospective patients pause.

Adding to the trust concerns, PeterMd holds an F rating with the Better Business Bureau — the lowest possible grade. An F rating from the BBB typically indicates a pattern of unresolved complaints, failure to respond to customer issues, or business practices that the Bureau considers problematic. Our research notes reference “questionable practices” associated with this provider, though specific details are difficult to verify given the limited public information available. The combination of a removed Trustpilot page and an F BBB rating creates a trust profile that is among the worst we have encountered in our reviews.

From a clinical perspective, PeterMd does not offer lab testing or dietitian support, and the quality of its medical providers has been flagged as low in our assessment. Without lab work, there is no mechanism to establish baseline health markers or monitor patients for potential side effects related to tirzepatide therapy. The narrow medication focus — only compounded tirzepatide — also limits options for patients who might benefit from semaglutide-based treatments instead.

Despite its relatively affordable pricing, PeterMd represents one of the higher-risk choices in the GLP-1 telehealth market. The convergence of a removed review platform, the lowest possible BBB grade, and reports of questionable practices paints a troubling picture. Our editorial team strongly advises prospective patients to exercise extreme caution and consider providers with transparent, verifiable track records before entrusting their health — and their money — to this platform.

PeterMd GLP-1 Medications

At a Glance